Evidence map›Paper›PMID 28841211›Full record

Trial reportBlood cancer journal2017

Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group.

J Hillengass, L A Moulopoulos, S Delorme, V Koutoulidis, J Mosebach, T Hielscher, M Drake, S V Rajkumar, B Oestergaard, N Abildgaard and 12 more

Registry-linked trialOpen access · goldAbstract readClinical TrialComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06212323 (Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial), which is not on this map. Cited by 82 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 5 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06212323 recruitingnot on this mapstarted 2024, after this paper: background citation

Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

TypeobservationalSponsorUniversity of UtahRan2024 to 2030Enrolled100ConditionsSmoldering Multiple MyelomaArmsPatients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.
3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 5 syntheses or guidelines pooled it, 171 citations in OpenAlex.

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Guideline
  2. Pooled it
  3. EANM guidelines on the use of [European journal of nuclear medicine and molecular imaging · 2024
    Guideline
  4. Pooled it
  5. Guideline
  6. Trial
  7. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 10 institutions in 7 countries.

J HillengassDepartment of Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany.
L A MoulopoulosFirst Department of Radiology, National and Kapodistrian University of Athens, School of Medicine, Areteion Hospital, Athens, Greece.
S DelormeDepartment of Radiology, German Cancer Research Center, Heidelberg, Germany.
V KoutoulidisFirst Department of Radiology, National and Kapodistrian University of Athens, School of Medicine, Areteion Hospital, Athens, Greece.
J MosebachDepartment of Radiology, German Cancer Research Center, Heidelberg, Germany.
T HielscherDepartment for Biostatistics, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0003-1277-310X
M DrakeDivision of Endocrinology, Mayo Clinic, Rochester, MN, USA.
S V RajkumarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
B OestergaardDepartment of Hematology, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
N AbildgaardDepartment of Hematology, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
M HingeDepartment of Hematology, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
T PlesnerDepartment of Hematology, Vejle Hospital and University of Southern Denmark, Vejle, Denmark.
Y SueharaDivision of Hematology and Oncology, Department of Medicine Kameda Medical Center, Kamogawa-shi, Japan.
K MatsueDivision of Hematology and Oncology, Department of Medicine Kameda Medical Center, Kamogawa-shi, Japan.
N WithofsDepartment of Nuclear Medicine, CHU de Liège, Belgium.
J CaersDepartment of Hematology, CHU de Liège, Belgium.
A WaageDepartment of Hematology, St Olavs Hospital, Norwegian University of Science and Technology, Trondheim, Norway.
H GoldschmidtDepartment of Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany.
M A DimopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece.
S LentzschDepartment of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York City, NY, USA.
B DurieCedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA, USA.
E TerposDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece.
German Cancer Research Center · DENational and Kapodistrian University of Athens · GRUniversity of Southern Denmark · DKCentre Hospitalier Universitaire de Liège · BEKameda Medical Center · JPMayo Clinic in Arizona · USCedars-Sinai Medical Center · USColumbia University Irving Medical Center · USHeidelberg University · DENorwegian University of Science and Technology · NO

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Peter Leif Bergsagel · 2015 to 2026
$25.5M
NCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

For decades, conventional skeletal survey (CSS) has been the standard imaging technique for multiple myeloma (MM). However, recently whole-body computed tomography (WBCT) has been implemented into the diagnostic criteria of MM. This analysis compares sensitivity and prognostic significance of WBCT and CSS in patients with smoldering MM (SMM) and MM. Fifty-four of 212 patients (25.5%) had a negative CSS and a positive WBCT for osteolytic lesions (P<0.0001). Of 66 patients with SMM based on CSS, 12 (22.2%) had osteolytic lesions on WBCT. In comparison, WBCT failed to detect some bone destructions in the appendicular skeleton possibly due to limitations of the field of view. Presence of lytic bone lesions in WBCT was of borderline prognostic significance (P=0.051) for SMM patients, with a median time to progression of 38 versus 82 months for those without bone destructions. In conclusion, WBCT identifies significantly more sites of bone destruction than CSS. More than 20% of patients with SMM according to CSS have in fact active MM detectable with WBCT. On the basis of this and other studies, WBCT (either computed tomography (CT) alone or as part of a positron emission tomography-CT protocol) should be considered the current standard for the detection of osteolytic lesions in MM.

Indexed as

Positron-Emission TomographyTomography, X-Ray ComputedAdultAgedAged, 80 and overDisease-Free SurvivalFemaleHumansMaleMiddle AgedMultiple MyelomaOsteolysisRetrospective StudiesSurvival Rate

Identifiers

PMID28841211
PMCPMC5596388
OpenAlexW2746958153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.